Ingredient or product comparison
Stacking GHK-Cu Glutathione Anti-Aging Research: Complete Protocol Comparison
GHK-Cu Dose 1–3 mg daily, reconstituted from lyophilized powder 2–5 mg applied transdermally after microneedling or chemical exfoliation 2 mg GHK-Cu SC + 1,000 mg glutathione IV weekly Subcutaneous achieves most consistent plasma levels; topical depends heavil
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu Dose
- 1–3 mg daily, reconstituted from lyophilized powder
- 2–5 mg applied transdermally after microneedling or chemical exfoliation
- 2 mg GHK-Cu SC + 1,000 mg glutathione IV weekly
- Subcutaneous achieves most consistent plasma levels; topical depends heavily on skin barrier integrity; IV combination produces highest short-term biomarker changes
- Glutathione Route
- Liposomal oral 500–1,000 mg, dosed 4–6 hours post-GHK-Cu
- Liposomal oral 500 mg, same-day dosing
- IV 1,000–2,000 mg, administered same session
- IV bypasses all absorption barriers but requires clinical setting; liposomal is viable for daily maintenance if dosed consistently for 8+ weeks
- Timing Strategy
- Sequential: GHK-Cu AM, glutathione midday
- Simultaneous application topically, glutathione oral separately
- Single IV session weekly, both compounds administered 30 minutes apart
- Sequential dosing aligns better with oxidative-surge timing from tissue repair; simultaneous is logistically simpler but less mechanistically targeted
- Adjunct Support
- N-acetylcysteine 600 mg to support endogenous GSH synthesis
- Vitamin C 1,000 mg to recycle oxidized glutathione
- Alpha-lipoic acid 300 mg to regenerate both glutathione and vitamin C
- NAC provides cysteine, the rate-limiting amino acid in glutathione synthesis; vitamin C extends glutathione's effective lifespan; ALA is the most versatile regenerator
- Duration to Measurable Effect
- 6–8 weeks for dermal thickness changes on ultrasound imaging
- 8–12 weeks for visible reduction in fine lines and photodamage
- 4–6 weeks for improved oxidative stress biomarkers (MDA, 8-OHdG)
- Tissue-level changes lag gene expression changes by weeks; biomarker improvements precede visible outcomes